Direct Oral Anticoagulant (DOAC) Reversal: Part 2
The Trauma Pro
DECEMBER 24, 2024
In the previous post, I reviewed some basic information on DOAC reversal. Five years ago, it was costly and questionably effective. So what has happened in the meantime? In this post, I’ll review a big trial the pharma company was excited about and make a few comments. ANNEXA-I Study This study sought to evaluate the hemostatic effect of Andexanet administration in patients taking a Factor Xa inhibitor who suffered an intracranial hemorrhage.
113 
Let's personalize your content